Real‐World Dose Adjustment and Switching of Interleukin‐17/23 Inhibitors for Thai Psoriasis
Dermatology Research and Practice · 2026-01 · 2026 (1)
DOI: 10.1155/drp/7998583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Research and Practice, online erschienen am 18.07.2026. Verfasst von Chayada Chaiyabutr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interleukin (IL)‐17 and IL‐23 inhibitors have transformed psoriasis care, delivering high clearance rates and quality‐of‐life gains. Nevertheless, inadequate response or adverse events can lead to treatment discontinuation or biologic switching. Dose modifications are also commonly implemented in routine practice to optimize efficacy, safety, and cost. The objective of this study is to characterize real‐world outcomes of dose adjustment and switching of IL‐17 and IL‐23 inhibitors in Thai patients with psoriasis. We retrospectively reviewed 173 treatment courses with IL‐17 inhibitors (secukinumab, ixekizumab, and brodalumab) and the IL‐23 inhibitor guselkumab, documenting loading regimens, maintenance dosing, efficacy to Week 52, and switching events. At Week 12, full loading and standard maintenance dosing were associated with higher response rates in most cases. Ixekizumab was least often given with a full loading dose or standard maintenance dosing. By Weeks 24 and 52, reduced‐dose regimens achieved comparable or better outcomes, suggesting careful patient selection. Thirty courses underwent biologic switching, predominantly for secondary failure. Intraclass switching among IL‐17 inhibitors predominated. Switching from IL‐23 to IL‐17 inhibitors potentially outperformed both intraclass IL‐17 switching or IL‐17‐to‐IL‐23 transitions. Erythrodermic psoriasis and higher baseline disease severity predicted switching, whereas incomplete loading doses and dose reductions did not. In conclusion, full loading and standard maintenance regimens facilitate early treatment response, while dose reduction in carefully selected patients can sustain long‐term disease control without increasing the risk of switching.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.
ORCID-Profile: Chayada Chaiyabutr, Thrit Hutachoke, Narumol Silpa-Archa, Leena Chularojanamontri, Chanisada Wongpraparut
Zitieren
APA
Chaiyabutr, C., Paringkarn, T., Woramongkol, T., Hutachoke, T., Silpa-Archa, N., Chularojanamontri, L., & Wongpraparut, C. (2026). Real‐World Dose Adjustment and Switching of Interleukin‐17/23 Inhibitors for Thai Psoriasis. Dermatology Research and Practice, 2026(1). https://doi.org/10.1155/drp/7998583
Vancouver
Chaiyabutr C, Paringkarn T, Woramongkol T, Hutachoke T, Silpa-Archa N, Chularojanamontri L, et al. Real‐World Dose Adjustment and Switching of Interleukin‐17/23 Inhibitors for Thai Psoriasis. Dermatology Research and Practice. 2026;2026(1). doi:10.1155/drp/7998583
BibTeX
@article{Chaiyabutr2026,
author = {Chaiyabutr, Chayada and Paringkarn, Teerapat and Woramongkol, Thanakorn and Hutachoke, Thrit and Silpa-Archa, Narumol and Chularojanamontri, Leena and Wongpraparut, Chanisada},
title = {Real‐World Dose Adjustment and Switching of Interleukin‐17/23 Inhibitors for Thai Psoriasis},
journal = {Dermatology Research and Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/drp/7998583}
}
EUVIMED